6 research outputs found
Inference of COVID-19 epidemiological distributions from Brazilian hospital data
Knowing COVID-19 epidemiological distributions, such as the time from patient
admission to death, is directly relevant to effective primary and secondary
care planning, and moreover, the mathematical modelling of the pandemic
generally. We determine epidemiological distributions for patients hospitalised
with COVID-19 using a large dataset () from the Brazilian
Sistema de Informa\c{c}\~ao de Vigil\^ancia Epidemiol\'ogica da Gripe database.
A joint Bayesian subnational model with partial pooling is used to
simultaneously describe the 26 states and one federal district of Brazil, and
shows significant variation in the mean of the symptom-onset-to-death time,
with ranges between 11.2-17.8 days across the different states, and a mean of
15.2 days for Brazil. We find strong evidence in favour of specific probability
density function choices: for example, the gamma distribution gives the best
fit for onset-to-death and the generalised log-normal for
onset-to-hospital-admission. Our results show that epidemiological
distributions have considerable geographical variation, and provide the first
estimates of these distributions in a low and middle-income setting. At the
subnational level, variation in COVID-19 outcome timings are found to be
correlated with poverty, deprivation and segregation levels, and weaker
correlation is observed for mean age, wealth and urbanicity
Estimating the COVID-19 infection fatality ratio accounting for seroreversion using statistical modelling.
Background: The infection fatality ratio (IFR) is a key statistic for estimating the burden of coronavirus disease 2019 (COVID-19) and has been continuously debated throughout the COVID-19 pandemic. The age-specific IFR can be quantified using antibody surveys to estimate total infections, but requires consideration of delay-distributions from time from infection to seroconversion, time to death, and time to seroreversion (i.e. antibody waning) alongside serologic test sensitivity and specificity. Previous IFR estimates have not fully propagated uncertainty or accounted for these potential biases, particularly seroreversion. Methods: We built a Bayesian statistical model that incorporates these factors and applied this model to simulated data and 10 serologic studies from different countries. Results: We demonstrate that seroreversion becomes a crucial factor as time accrues but is less important during first-wave, short-term dynamics. We additionally show that disaggregating surveys by regions with higher versus lower disease burden can inform serologic test specificity estimates. The overall IFR in each setting was estimated at 0.49-2.53%. Conclusion: We developed a robust statistical framework to account for full uncertainties in the parameters determining IFR. We provide code for others to apply these methods to further datasets and future epidemics
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Manaus, Brazil, resurged in late 2020 despite previously high levels of infection. Genome sequencing of viruses sampled in Manaus between November 2020 and January 2021 revealed the emergence and circulation of a novel SARS-CoV-2 variant of concern. Lineage P.1 acquired 17 mutations, including a trio in the spike protein (K417T, E484K, and N501Y) associated with increased binding to the human ACE2 (angiotensin-converting enzyme 2) receptor. Molecular clock analysis shows that P.1 emergence occurred around mid-November 2020 and was preceded by a period of faster molecular evolution. Using a two-category dynamical model that integrates genomic and mortality data, we estimate that P.1 may be 1.7- to 2.4-fold more transmissible and that previous (non-P.1) infection provides 54 to 79% of the protection against infection with P.1 that it provides against non-P.1 lineages. Enhanced global genomic surveillance of variants of concern, which may exhibit increased transmissibility and/or immune evasion, is critical to accelerate pandemic responsiveness
Data from: Evolution and epidemic spread of SARS-CoV-2 in Brazil
Brazil currently has one of the fastest growing SARS-CoV-2 epidemics in the world. Owing to limited available data, assessments of the impact of non-pharmaceutical interventions (NPIs) on virus spread remain challenging. Using a mobility-driven transmission model, we show that NPIs reduced the reproduction number from >3 to 1–1.6 in São Paulo and Rio de Janeiro. Sequencing of 427 new genomes and analysis of a geographically representative genomic dataset identified >100 international virus introductions in Brazil. We estimate that most (76%) of the Brazilian strains fell in three clades that were introduced from Europe between 22 February11 March 2020. During the early epidemic phase, we found that SARS-CoV-2 spread mostly locally and within-state borders. After this period, despite sharp decreases in air travel, we estimated multiple exportations from large urban centers that coincided with a 25% increase in average travelled distances in national flights. This study sheds new light on the epidemic transmission and evolutionary trajectories of SARS-CoV-2 lineages in Brazil, and provide evidence that current interventions remain insufficient to keep virus transmission under control in the country